{"entity":{"id":"stx-0712","kind":"drug","name":"STX-0712","aka":[],"tldr":"STX-0712 is an experimental cyTAC with ADCC-enhanced platform antibody from Solu Therapeutics, in phase 1 trials for chronic myelomonocytic leukaemia and acute myeloid leukaemia.","summary":"STX-0712 is a cyTAC (cytotoxicity targeting chimera) with ADCC-enhanced platform antibody from Solu Therapeutics. A CyTAC targeting the GPCR CCR2, a marker expressed at high levels on pathogenic monocytes, designed to eliminate those cells. Its furthest stage is phase 1, for chronic myelomonocytic leukaemia and acute myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06950034 recruiting, title includes CMML and AML (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Solu Therapeutics: solutherapeutics.com","url":"https://solutherapeutics.com/"},{"label":"Solu Therapeutics: solutherapeutics.com","url":"https://solutherapeutics.com/"},{"label":"Solu Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06950034"},{"label":"ClinicalTrials.gov: trials of STX-0712","url":"https://clinicaltrials.gov/search?intr=STX-0712"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cmml","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["solu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06950034"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"STX-0712","modality":"CyTAC (cytotoxicity targeting chimera) with ADCC-enhanced platform antibody","mechanism":"A CyTAC targeting the GPCR CCR2, a marker expressed at high levels on pathogenic monocytes, designed to eliminate those cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/stx-0712/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"}],"company":[{"id":"solu-therapeutics","kind":"company","name":"Solu Therapeutics","route":"/companies/solu-therapeutics/"}],"trial":[{"id":"nct06950034","kind":"trial","name":"A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)","route":"/trials/nct06950034/"}]}}